-       Report 
- June 2023
-  112 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
          -       Report 
- October 2024
-  200 Pages 
- Global 
   From       €3354EUR$3,750USD£2,950GBP 
          -       Report 
- October 2022
-  163 Pages 
- Global 
   From       €3220EUR$3,600USD£2,832GBP 
          -       Report 
- November 2022
-  150 Pages 
- Global 
   From       €4338EUR$4,850USD£3,816GBP 
          -       Report 
- October 2024
-  104 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
           -       Report 
- July 2023
-  95 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- April 2024
-  132 Pages 
- Global 
   From       €850EUR$950USD£747GBP 
          -       Report 
- November 2021
-  1032 Pages 
- Global 
   From       €4472EUR$5,000USD£3,934GBP 
               Genomic biomarkers are a type of biomarker that are used to identify and measure genetic material in a biological sample. They are used to detect genetic variations that can be used to diagnose and monitor diseases, predict drug response, and identify individuals at risk for certain conditions. Genomic biomarkers are used in a variety of applications, including personalized medicine, drug development, and diagnostics.
Genomic biomarkers are typically identified through the analysis of DNA, RNA, and    proteins. They can be used to detect genetic variations that are associated with diseases, such as cancer, and to identify individuals at risk for certain conditions. Genomic biomarkers can also be used to predict drug response and to monitor the progression of diseases.
The genomic biomarker market is expected to grow significantly in the coming years, driven by advances in technology and the increasing demand for personalized medicine. Companies in the market include Illumina, Thermo Fisher Scientific, Qiagen, Agilent Technologies, and Roche. Show Less   Read more